258 related articles for article (PubMed ID: 17905172)
1. Protective immunization in mice against group B streptococci using encapsulated C5a peptidase.
Santillan DA; Andracki ME; Hunter SK
Am J Obstet Gynecol; 2008 Jan; 198(1):114.e1-6. PubMed ID: 17905172
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine model.
Santillan DA; Rai KK; Santillan MK; Krishnamachari Y; Salem AK; Hunter SK
Am J Obstet Gynecol; 2011 Sep; 205(3):249.e1-8. PubMed ID: 21802065
[TBL] [Abstract][Full Text] [Related]
3. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice.
Cleary PP; Matsuka YV; Huynh T; Lam H; Olmsted SB
Vaccine; 2004 Oct; 22(31-32):4332-41. PubMed ID: 15474726
[TBL] [Abstract][Full Text] [Related]
4. Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice.
Xue G; Yu L; Li S; Shen X
FEMS Immunol Med Microbiol; 2010 Mar; 58(2):202-10. PubMed ID: 19912341
[TBL] [Abstract][Full Text] [Related]
5. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate.
Paoletti LC; Pinel J; Kennedy RC; Kasper DL
J Infect Dis; 2000 Feb; 181(2):653-8. PubMed ID: 10669351
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII.
Paoletti LC; Pinel J; Johnson KD; Reinap B; Ross RA; Kasper DL
J Infect Dis; 1999 Sep; 180(3):892-5. PubMed ID: 10438388
[TBL] [Abstract][Full Text] [Related]
7. Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Infect Immun; 2000 Oct; 68(10):5749-55. PubMed ID: 10992481
[TBL] [Abstract][Full Text] [Related]
8. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
9. Poly(lactide-co-glycolide) microspheres: a potent oral delivery system to elicit systemic immune response against inactivated rabies virus.
Ramya R; Verma PC; Chaturvedi VK; Gupta PK; Pandey KD; Madhanmohan M; Kannaki TR; Sridevi R; Anukumar B
Vaccine; 2009 Mar; 27(15):2138-43. PubMed ID: 19356617
[TBL] [Abstract][Full Text] [Related]
10. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development.
Shet A; Kaplan EL; Johnson DR; Cleary PP
J Infect Dis; 2003 Sep; 188(6):809-17. PubMed ID: 12964111
[TBL] [Abstract][Full Text] [Related]
11. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.
Wang D; Molavi O; Lutsiak ME; Elamanchili P; Kwon GS; Samuel J
J Pharm Pharm Sci; 2007; 10(2):217-30. PubMed ID: 17706180
[TBL] [Abstract][Full Text] [Related]
12. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen.
Lin FY; Weisman LE; Azimi PH; Philips JB; Clark P; Regan J; Rhoads GG; Frasch CE; Gray BM; Troendle J; Brenner RA; Moyer P; Clemens JD
J Infect Dis; 2004 Sep; 190(5):928-34. PubMed ID: 15295698
[TBL] [Abstract][Full Text] [Related]
13. Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice.
Cheng Q; Debol S; Lam H; Eby R; Edwards L; Matsuka Y; Olmsted SB; Cleary PP
Infect Immun; 2002 Nov; 70(11):6409-15. PubMed ID: 12379721
[TBL] [Abstract][Full Text] [Related]
14. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.
Park HS; Cleary PP
Infect Immun; 2005 Dec; 73(12):7878-86. PubMed ID: 16299278
[TBL] [Abstract][Full Text] [Related]
15. Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.
Yang HH; Madoff LC; Guttormsen HK; Liu YD; Paoletti LC
Infect Immun; 2007 Jul; 75(7):3455-61. PubMed ID: 17470542
[TBL] [Abstract][Full Text] [Related]
16. Cross-protection between group A and group B streptococci due to cross-reacting surface proteins.
Stâlhammar-Carlemalm M; Areschoug T; Larsson C; Lindahl G
J Infect Dis; 2000 Jul; 182(1):142-9. PubMed ID: 10882591
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice.
Hunter SK; Andracki ME; Krieg AM
Am J Obstet Gynecol; 2001 Nov; 185(5):1174-9. PubMed ID: 11717653
[TBL] [Abstract][Full Text] [Related]
18. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
19. [Recombinant fragments of conservative proteins of group B streptococci as a basis of specific vaccine].
Suvorov AN; Grabovskaia KB; Leont'eva GF; Meringova LF; Koroleva IN; Duplik NV; Totolian AA
Zh Mikrobiol Epidemiol Immunobiol; 2010; (2):44-50. PubMed ID: 20465000
[TBL] [Abstract][Full Text] [Related]
20. Conjugate vaccines against group B Streptococcus types IV and VII.
Paoletti LC; Kasper DL
J Infect Dis; 2002 Jul; 186(1):123-6. PubMed ID: 12089673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
